The triplet combination of encorafenib (Braftovi), cetuximab (Erbitux), and nivolumab (Opdivo) exhibited safety and early efficacy in patients with mi...

Daily use of interferon-alpha (IFN-α) as a nasal spray was found to reduce the incidence of COVID-19 for adult patients with cancer, according to resu...

After a long Labor Day Weekend, the FDA has made a number of decisions regarding various oncology treatments and has set meetings with a few developer...

During a conversation with CancerNetwork®, Nicholas James Hornstein, MD, PhD, discussed results from the phase 2 INTERCEPT-TT trial (NCT05343013) that...

Outpatient step-up dosing of bispecific antibody therapy in multiple myeloma has been shown to be feasible in several academic centers and recent clin...

In a recent episode of the Oncology-on-the-Go podcast in collaboration with the American Psychosocial Oncology Society (APOS), host Daniel C. McFarlan...

In the phase 2 INTERCEPT-TT trial (NCT05343013), TAS-102 demonstrated improved levels of circulating tumor DNA (ctDNA) clearance vs a synthetic contro...

As part of a collaboration between CancerNetwork® and KidneyCAN, Michael B. Atkins, MD, spoke about novel biomarkers that may play a role in the detec...

The phase 2 INTERCEPT-TT trial showed that TAS-102 induced ctDNA clearance following adjuvant chemotherapy in patients with colorectal cancer.

Pediatric patients self-reported symptom burden using the SSPedi tool, which observed symptom burden from baseline, 4 weeks, and 8 weeks.